Showing posts with label Cancer. Show all posts
Showing posts with label Cancer. Show all posts

Sunday, March 19, 2023

Actor Sam Neill reveals blood cancer diagnosis

WELLINGTON, New Zealand - Actor Sam Neill has revealed he is being treated for stage-three blood cancer, writing in a memoir that he was "possibly dying" from the illness diagnosed a year ago.

The New Zealander, who burst to fame after starring as Dr Alan Grant in the 1993 blockbuster "Jurassic Park", said he began treatment last March for non-Hodgkin lymphoma.

Neill, 75, makes the revelation in his book "Did I Ever Tell You This?", which is being released next week.

In the opening chapter, written while undergoing chemotherapy, Neill said: "The thing is, I'm crook. Possibly dying. I may have to speed this up." 

The actor told The Guardian he is now in remission but will continue to undergo chemotherapy for the remainder of his life.

"I can't pretend that the last year hasn't had its dark moments," he said.

"But those dark moments throw the light into sharp relief, you know, and have made me grateful for every day and immensely grateful for all my friends. Just pleased to be alive."

Neill's vast acting career began in the 1970s and has spanned dozens of roles in TV and film, including "Peaky Blinders", "The Hunt for Red October", and "The Piano". 

He is currently preparing for a role in a television adaptation of Liane Moriarty's bestselling novel "Apples Never Fall", which will be filmed in Australia.

When he's not acting, Neill also runs vineyards in the picturesque Central Otago region of New Zealand's South Island.

Agence France Presse

Wednesday, February 20, 2019

Vaccine could virtually eliminate cervical cancer – study


PARIS, France – The rapid scale-up of the human papillomavirus (HPV) vaccine could virtually eliminate cervical cancer in a handful of rich countries within three decades, and in most other nations by century’s end, researchers said Wednesday.

Without screening and HPV vaccination, more than 44 million women will likely be diagnosed with the disease over the next 50 years, they reported in The Lancet Oncology, a medical journal.

Two thirds of these cases — and an estimated 15 million deaths — would occur in low- and medium-income countries.


By contrast, the rapid deployment starting in 2020 of screening and vaccination could prevent more than 13 million cervical cancers by mid-century worldwide, and lower the number of cases to below four-per-100,000 women, the study found.

“This is a potential threshold for considering cervical cancer to be eliminated as a major public health problem,” the authors said in a statement.

Earlier this month, the World Health Organization (WHO) reported 570,000 new cases worldwide in 2018, making it the fourth most common cancer for women after breast, colon and lung cancer.

The disease claims the lives of more than 300,000 women every year, mostly in lower income nations.

“Despite the enormity of the problem, our findings suggest that global elimination is within reach,” said lead author Karen Canfell, a professor at the Cancer Council New South Wales, in Sydney.

Achieving that goal, however, depends on “both high coverage of HPV vaccination and cervical screening,” she added.

Transmitted sexually, HPV is extremely common and includes more than 100 types of virus, at least 14 of them cancer-causing.

The viruses have also been linked to cancers of the anus, vulva, vagina and penis.

It takes 15 to 20 years for cervical cancer to develop in women with normal immune systems. If the immune system is weak or compromised — by HIV infection, for example — the cancer can develop far more quickly.

Clinical trials have shown that HPV vaccines are safe and effective against the two HPV strains — types 16 and 18 — responsible for 70 percent of cervical cancer cases.

The study’s projections presume the vaccination of 80 percent of girls 12 to 15 years old starting in 2020, and that at least 70 percent of women undergo screening twice in their lifetime.

This would push the prevalence of the disease below the bar of 4/100,000 women in countries such as the United States, Canada, Britain and France by 2059, and in mid-income countries such as Brazil and China by 2069, the authors calculate. /cbb

source: technology.inquirer.net

Sunday, October 21, 2018

Immunotherapy scores a first win against some breast cancers


For the first time, one of the new immunotherapy drugs has shown promise against breast cancer in a large study that combined it with chemotherapy to treat an aggressive form of the disease. But the benefit for most women was small, raising questions about whether the treatment is worth its high cost and side effects.

Results were discussed Saturday at a cancer conference in Munich and published by the New England Journal of Medicine.


Drugs called checkpoint inhibitors have transformed treatment of many types of cancer by removing a chemical brake that keeps the immune system from killing tumor cells. Their discovery recently earned scientists a Nobel Prize. Until now, though, they haven’t proved valuable against breast cancer.


The new study tested one from Roche called Tecentriq plus chemo versus chemo alone in 902 women with advanced triple-negative breast cancer. About 15 percent of cases are this type — their growth is not fueled by the hormones estrogen or progesterone, or the gene that Herceptin targets, making them hard to treat.

Women in the study who received Tecentriq plus chemo went two months longer on average without their cancer worsening compared with those on chemo alone — a modest benefit. The combo did not significantly improve survival in an early look before long-term follow-up is complete.

Previous studies found that immunotherapies work best in patients with high levels of a protein that the drugs target, and the plan for the breast cancer study called for analyzing how women fared according to that factor if Tecentriq improved survival overall.

The drug failed that test, but researchers still looked at protein-level results and saw encouraging signs. Women with high levels who received the combo treatment lived roughly 25 months on average versus about 15 months for women given chemo alone.


That’s a big difference, but it will take more time to see if there’s a reliable way to predict benefit, said Dr. Jennifer Litton of the MD Anderson Cancer Center in Houston. She had no role in running the study but enrolled some patients in it, and oversees 14 others testing immunotherapies.

“We’re really hopeful that we can identify a group of women who can get a much bigger and longer response,” she said.

Another breast cancer specialist with no role in the study, Dr. Michael Hassett at Dana-Farber Cancer Institute in Boston, said he felt “cautious excitement” that immunotherapy may prove helpful for certain breast cancer patients.

Side effects need a close look, both doctors said. Nearly all study participants had typical chemo side effects such as nausea or low blood cell counts, but serious ones were more common with the combo treatment and twice as many women on it stopped treatment for that reason.



This undated fluorescence-colored microscope image made available by the National Institutes of Health in September 2016 shows a culture of human breast cancer cells. For the first time, one of the new immunotherapy drugs has shown promise against breast cancer in a large study that combined it with chemotherapy to treat an aggressive form of the disease. Results were discussed Saturday, Oct. 20, 2018 at a European Society for Medical Oncology conference in Munich and published by the New England Journal of Medicine. AP

For the first time, one of the new immunotherapy drugs has shown promise against breast cancer in a large study that combined it with chemotherapy to treat an aggressive form of the disease. But the benefit for most women was small, raising questions about whether the treatment is worth its high cost and side effects.

Results were discussed Saturday at a cancer conference in Munich and published by the New England Journal of Medicine.


Drugs called checkpoint inhibitors have transformed treatment of many types of cancer by removing a chemical brake that keeps the immune system from killing tumor cells. Their discovery recently earned scientists a Nobel Prize. Until now, though, they haven’t proved valuable against breast cancer.


The new study tested one from Roche called Tecentriq plus chemo versus chemo alone in 902 women with advanced triple-negative breast cancer. About 15 percent of cases are this type — their growth is not fueled by the hormones estrogen or progesterone, or the gene that Herceptin targets, making them hard to treat.

Women in the study who received Tecentriq plus chemo went two months longer on average without their cancer worsening compared with those on chemo alone — a modest benefit. The combo did not significantly improve survival in an early look before long-term follow-up is complete.

Previous studies found that immunotherapies work best in patients with high levels of a protein that the drugs target, and the plan for the breast cancer study called for analyzing how women fared according to that factor if Tecentriq improved survival overall.

The drug failed that test, but researchers still looked at protein-level results and saw encouraging signs. Women with high levels who received the combo treatment lived roughly 25 months on average versus about 15 months for women given chemo alone.


That’s a big difference, but it will take more time to see if there’s a reliable way to predict benefit, said Dr. Jennifer Litton of the MD Anderson Cancer Center in Houston. She had no role in running the study but enrolled some patients in it, and oversees 14 others testing immunotherapies.

“We’re really hopeful that we can identify a group of women who can get a much bigger and longer response,” she said.

Another breast cancer specialist with no role in the study, Dr. Michael Hassett at Dana-Farber Cancer Institute in Boston, said he felt “cautious excitement” that immunotherapy may prove helpful for certain breast cancer patients.

Side effects need a close look, both doctors said. Nearly all study participants had typical chemo side effects such as nausea or low blood cell counts, but serious ones were more common with the combo treatment and twice as many women on it stopped treatment for that reason.


Three of the six deaths from side effects in the combo group were blamed on the treatment itself; only one of three such deaths in the chemo group was.

Cost is another concern. Tecentriq is $12,500 a month. The chemo in this study was Celgene’s Abraxane, which costs about $3,000 per dose plus doctor fees for the IV treatments. Older chemo drugs cost less but require patients to use a steroid to prevent allergic reactions that might interfere with the immunotherapy. Abraxane was chosen because it avoids the need for a steroid, said one study leader, Dr. Sylvia Adams of NYU Langone Health.

The study was sponsored by Roche and many study leaders consult or work for the company or own stock in it. /cbb

source: technology.inquirer.net

Sunday, August 26, 2018

Presidents, lawmakers honor McCain’s life of service


WASHINGTON — Presidents and lawmakers from both parties honored Sen. John McCain’s decades of service to his country in the hours after his death Saturday. President Donald Trump, who once criticized McCain for being taken prisoner during the Vietnam War, said his “deepest sympathies and respect” went out to McCain’s family.

McCain, 81, died at his ranch in Arizona after a yearlong battle with brain cancer. On Saturday night, a black hearse accompanied by a police motorcade could be seen driving away from the ranch near Sedona where the Republican senator spent his final weeks.


Trump’s brief Twitter statement said “hearts and prayers” are with the McCain family. First lady Melania Trump thanked McCain for his service to the nation, which included more than five years as a prisoner of war and six terms in the Senate.

Trump and McCain were at odds until the end. The president, who mocked McCain’s capture in Vietnam during the 2016 campaign, jabbed at the senator even after his illness for voting against Republican efforts to roll back President Barack Obama’s health care law. Earlier this summer, McCain issued a blistering statement criticizing Trump’s meeting with Russian President Vladimir Putin.

Former presidents, including those who blocked McCain’s own White House ambitions, offered emotional tributes.

Obama, who triumphed over McCain in the 2008 election, said that despite their differences, McCain and he shared a “fidelity to something higher – the ideals for which generations of Americans and immigrants alike have fought, marched, and sacrificed.”

Obama said the two political opponents “saw our political battles, even, as a privilege, something noble, an opportunity to serve as stewards of those high ideals at home, and to advance them around the world.”

Former President George W. Bush, who defeated McCain for the 2000 Republican presidential nomination, called his one-time political rival “man of deep conviction and a patriot of the highest order” and a “friend whom I’ll deeply miss.”

Bush was among those expected to speak at McCain’s funeral.

McCain was the son and grandson of admirals and followed them to the U.S. Naval Academy. A pilot, he was shot down over Vietnam and held as a prisoner of war for more than five years. He went on to win a seat in the House and in 1986, the Senate, where he served for the rest of his life.

Senate Majority Leader Mitch McConnell called McCain a “fascinating personality.”

“He would occasionally be in a bad place with various members, including myself, and when this would blow over it was like nothing ever happened,” McConnell said Saturday after a GOP state dinner in Lexington, Kentucky. “He also had a wicked sense of humor and it made every tense moment come out better.”

Former Vice President Joe Biden, who developed a friendship with McCain while they served together in the Senate, said the Arizona lawmaker will “cast a long shadow.”

“The spirit that drove him was never extinguished: we are here to commit ourselves to something bigger than ourselves,” Biden said.


McCain is expected to be remembered in Arizona and Washington before being buried, likely this week, at the Naval Academy Cemetery on a peninsula overlooking the Severn River.

Other plans were taking shape, too. Sen. Chuck Schumer, D-N.Y., announced that he wants to name the Senate building that housed McCain’s suite of offices after the Arizona senator, who served as chairman of the Commerce Committee and the Senate Armed Services Committee.

“As you go through life, you meet few truly great people. John McCain was one of them,” Schumer said. “Maybe most of all, he was a truth teller – never afraid to speak truth to power in an era where that has become all too rare.”

source: newsinfo.inquirer.net

Thursday, August 16, 2018

‘Queen of Soul’ Aretha Franklin has died


DETROIT  — Aretha Franklin, the undisputed “Queen of Soul” who sang with matchless style on such classics as “Think,” ”I Say a Little Prayer” and her signature song, “Respect,” and stood as a cultural icon around the globe, has died at age 76 from advanced pancreatic cancer.

Publicist Gwendolyn Quinn tells The Associated Press through a family statement that Franklin died Thursday at 9:50 a.m. at her home in Detroit. The statement said “Franklin’s official cause of death was due to advance pancreatic cancer of the neuroendocrine type, which was confirmed by Franklin’s oncologist, Dr. Philip Phillips of Karmanos Cancer Institute” in Detroit.

The family added: “In one of the darkest moments of our lives, we are not able to find the appropriate words to express the pain in our heart. We have lost the matriarch and rock of our family. The love she had for her children, grandchildren, nieces, nephews, and cousins knew no bounds.”
The statement continued:


“We have been deeply touched by the incredible outpouring of love and support we have received from close friends, supporters and fans all around the world. Thank you for your compassion and prayers. We have felt your love for Aretha and it brings us comfort to know that her legacy will live on. As we grieve, we ask that you respect our privacy during this difficult time.”

Funeral arrangements will be announced in the coming days.

Franklin, who had battled undisclosed health issues in recent years, had in 2017 announced her retirement from touring.

A professional singer and accomplished pianist by her late teens, a superstar by her mid-20s, Franklin had long ago settled any arguments over who was the greatest popular vocalist of her time. Her gifts, natural and acquired, were a multi-octave mezzo-soprano, gospel passion and training worthy of a preacher’s daughter, taste sophisticated and eccentric, and the courage to channel private pain into liberating song.

She recorded hundreds of tracks and had dozens of hits over the span of a half century, including 20 that reached No. 1 on the R&B charts. But her reputation was defined by an extraordinary run of top 10 smashes in the late 1960s, from the morning-after bliss of “(You Make Me Feel Like) A Natural Woman,” to the wised-up “Chain of Fools” to her unstoppable call for “Respect.”

Her records sold millions of copies and the music industry couldn’t honor her enough. Franklin won 18 Grammy awards. In 1987, she became the first woman inducted into the Rock and Roll Hall of Fame.

Fellow singers bowed to her eminence and political and civic leaders treated her as a peer. The Rev. Martin Luther King Jr. was a longtime friend, and she sang at the dedication of King’s memorial, in 2011. She performed at the inaugurations of Presidents Bill Clinton and Jimmy Carter, and at the funeral for civil rights pioneer Rosa Parks. Clinton gave Franklin the National Medal of Arts. President George W. Bush awarded her the Presidential Medal of Freedom, the nation’s highest civilian honor, in 2005.

Franklin’s best-known appearance with a president was in January 2009, when she sang “My Country ’tis of Thee” at Barack Obama’s inauguration. She wore a gray felt hat with a huge, Swarovski rhinestone-bordered bow that became an Internet sensation and even had its own website. In 2015, she brought Obama and others to tears with a triumphant performance of “Natural Woman” at a Kennedy Center tribute to the song’s co-writer, Carole King.



Franklin endured the exhausting grind of celebrity and personal troubles dating back to childhood. She was married from 1961 to 1969 to her manager, Ted White, and their battles are widely believed to have inspired her performances on several songs, including “(Sweet Sweet Baby) Since You’ve Been Gone,” ”Think” and her heartbreaking ballad of despair, “Ain’t No Way.” The mother of two sons by age 16 (she later had two more), she was often in turmoil as she struggled with her weight, family problems and financial predicaments. Her best known producer, Jerry Wexler, nicknamed her “Our Lady of Mysterious Sorrows.”

Franklin married actor Glynn Turman in 1978 in Los Angeles but returned to her hometown of Detroit the following year after her father was shot by burglars and left semi-comatose until his death in 1984. She and Turman divorced that year.

Despite growing up in Detroit, and having Smokey Robinson as a childhood friend, Franklin never recorded for Motown Records; stints with Columbia and Arista were sandwiched around her prime years with Atlantic Records. But it was at Detroit’s New Bethel Baptist Church, where her father was pastor, that Franklin learned the gospel fundamentals that would make her a soul institution.

Aretha Louise Franklin was born March 25, 1942, in Memphis, Tennessee. The Rev. C.L. Franklin soon moved his family to Buffalo, New York, then to Detroit, where the Franklins settled after the marriage of Aretha’s parents collapsed and her mother (and reputed sound-alike) Barbara returned to Buffalo.

C.L. Franklin was among the most prominent Baptist ministers of his time. He recorded dozens of albums of sermons and music and knew such gospel stars as Marion Williams and Clara Ward, who mentored Aretha and her sisters Carolyn and Erma. (Both sisters sang on Aretha’s records, and Carolyn also wrote “Ain’t No Way” and other songs for Aretha). Music was the family business and performers from Sam Cooke to Lou Rawls were guests at the Franklin house. In the living room, the shy young Aretha awed friends with her playing on the grand piano.



Franklin occasionally performed at New Bethel Baptist throughout her career; her 1987 gospel album “One Lord One Faith One Baptism” was recorded live at the church.
Her most acclaimed gospel recording came in 1972 with the Grammy-winning album “Amazing Grace,” which was recorded live at New Temple Missionary Baptist Church in South Central Los Angeles and featured gospel legend James Cleveland, along with her own father (Mick Jagger was one of the celebrities in the audience). It became one of of the best-selling gospel albums ever.

The piano she began learning at age 8 became a jazzy component of much of her work, including arranging as well as songwriting. “If I’m writing and I’m producing and singing, too, you get more of me that way, rather than having four or five different people working on one song,” Franklin told The Detroit News in 2003.

Franklin was in her early teens when she began touring with her father, and she released a gospel album in 1956 through J-V-B Records. Four years later, she signed with Columbia Records producer John Hammond, who called Franklin the most exciting singer he had heard since a vocalist he promoted decades earlier, Billie Holiday. Franklin knew Motown founder Berry Gordy Jr. and considered joining his label, but decided it was just a local company at the time.

Franklin recorded several albums for Columbia Records over the next six years. She had a handful of minor hits, including “Rock-A-Bye Your Baby With a Dixie Melody” and “Runnin’ Out of Fools,” but never quite caught on as the label tried to fit into her a variety of styles, from jazz and show songs to such pop numbers as “Mockingbird.” Franklin jumped to Atlantic Records when her contract ran out, in 1966.

“But the years at Columbia also taught her several important things,” critic Russell Gersten later wrote. “She worked hard at controlling and modulating her phrasing, giving her a discipline that most other soul singers lacked. She also developed a versatility with mainstream music that gave her later albums a breadth that was lacking on Motown LPs from the same period.

“Most important, she learned what she didn’t like: to do what she was told to do.”

At Atlantic, Wexler teamed her with veteran R&B musicians from Fame Studios in Muscle Shoals, and the result was a tougher, soulful sound, with call-and-response vocals and Franklin’s gospel-style piano, which anchored “I Say a Little Prayer,” ”Natural Woman” and others.

Of Franklin’s dozens of hits, none was linked more firmly to her than the funky, horn-led march “Respect” and its spelled out demand for “R-E-S-P-E-C-T.”
Writing in Rolling Stone magazine in 2004, Wexler said: “It was an appeal for dignity combined with a blatant lubricity. There are songs that are a call to action. There are love songs. There are sex songs. But it’s hard to think of another song where all those elements are combined.”

Franklin had decided she wanted to “embellish” the R&B song written by Otis Redding, whose version had been a modest hit in 1965, Wexler said.

“When she walked into the studio, it was already worked out in her head,” the producer wrote. “Otis came up to my office right before ‘Respect’ was released, and I played him the tape. He said, ‘She done took my song.’ He said it benignly and ruefully. He knew the identity of the song was slipping away from him to her.”

In a 2004 interview with the St. Petersburg (Florida) Times, Franklin was asked whether she sensed in the ’60s that she was helping change popular music.

“Somewhat, certainly with ‘Respect,’ that was a battle cry for freedom and many people of many ethnicities took pride in that word,” she answered. “It was meaningful to all of us.”

In 1968, Franklin was pictured on the cover of Time magazine and had more than 10 Top 20 hits in 1967 and 1968. At a time of rebellion and division, Franklin’s records were a musical union of the church and the secular, man and woman, black and white, North and South, East and West. They were produced and engineered by New Yorkers Wexler and Tom Dowd, arranged by Turkish-born Arif Mardin and backed by an interracial assembly of top session musicians based mostly in Alabama.

Her popularity faded during the 1970s despite such hits as the funky “Rock Steady” and such acclaimed albums as the intimate “Spirit in the Dark.” But her career was revived in 1980 with a cameo appearance in the smash movie “The Blues Brothers” and her switch to Arista Records. Franklin collaborated with such pop and soul artists as Luther Vandross, Elton John, Whitney Houston and George Michael, with whom she recorded a No. 1 single, “I Knew You Were Waiting (for Me).” Her 1985 album “Who’s Zoomin’ Who” received some of her best reviews and included such hits as the title track and “Freeway of Love.”

Critics consistently praised Franklin’s singing but sometimes questioned her material; she covered songs by Stephen Sondheim, Bread, the Doobie Brothers. For Aretha, anything she performed was “soul.”

From her earliest recording sessions at Columbia, when she asked to sing “Over the Rainbow,” she defied category. The 1998 Grammys gave her a chance to demonstrate her range. Franklin performed “Respect,” then, with only a few minutes’ notice, filled in for an ailing Luciano Pavarotti and drew rave reviews for her rendition of “Nessun Dorma,” a stirring aria for tenors from Puccini’s “Turandot.”

“I’m sure many people were surprised, but I’m not there to prove anything,” Franklin told The Associated Press. “Not necessary.”
Fame never eclipsed Franklin’s charitable works, or her loyalty to Detroit.

Franklin sang the national anthem at Super Bowl in her hometown in 2006, after grousing that Detroit’s rich musical legacy was being snubbed when the Rolling Stones were chosen as halftime performers.

“I didn’t think there was enough (Detroit representation) by any means,” she said. “And it was my feeling, ‘How dare you come to Detroit, a city of legends — musical legends, plural — and not ask one or two of them to participate?’ That’s not the way it should be.”

Franklin did most of her extensive touring by bus after Redding’s death in a 1967 plane crash, and a rough flight to Detroit in 1982 left her with a fear of flying that anti-anxiety tapes and classes couldn’t help. She told Time in 1998 that the custom bus was a comfortable alternative: “You can pull over, go to Red Lobster. You can’t pull over at 35,000 feet.”

She only released a few albums over the past two decades, including “A Rose is Still a Rose,” which featured songs by Sean “Diddy” Combs, Lauryn Hill and other contemporary artists, and “So Damn Happy,” for which Franklin wrote the gratified title ballad. Franklin’s autobiography, “Aretha: From These Roots,” came out in 1999, when she was in her 50s. But she always made it clear that her story would continue.

“Music is my thing, it’s who I am. I’m in it for the long run,” she told The Associated Press in 2008. “I’ll be around, singing, ‘What you want, baby I got it.’ Having fun all the way.” /ee

source: entertainment.inquirer.net

Monday, June 4, 2018

No need for chemo in many breast and lung cancers – study


TAMPA, United States — Two major studies released Sunday show that many people with breast and lung cancers may forgo chemotherapy and still live longer, signaling a waning need for what was long seen as the standard of cancer care.

The findings were released at the American Society of Clinical Oncology (ASCO) meeting in Chicago, the world’s largest annual cancer conference.

The first study, described as the largest breast cancer treatment trial to date, found that the majority of women with a common form of breast cancer may be able to skip chemotherapy and its toxic, and often debilitating, side effects after surgery depending on their score on a genetic test.

As many as 65,000 women in the United States alone could be affected by the findings.

Until now, women have faced considerable uncertainty about whether to add chemo to hormone therapy after a diagnosis with hormone-receptor positive, HER-2 negative breast cancer when found at an early stage, before it has spread to the lymph nodes.

“With results of this groundbreaking study, we now can safely avoid chemotherapy in about 70 percent of patients who are diagnosed with the most common form of breast cancer,” said co-author Kathy Albain, an oncologist at Loyola Medicine in a Chicago suburb.

A 21-gene test called Oncotype DX, available since 2004, has helped guide some decisions on proper care after surgery.

A high recurrence score, above 25, means chemo is advised to ward off a recurrence, while a low score, below 10, means it is not.

The current study focused on those whose scores were in the middle range, from 11 to 25.

More than 10,000 women, aged 18 to 75, were randomly assigned to receive chemotherapy followed by hormone therapy, or hormone therapy alone.

Researchers studied their outcomes, including whether or not cancer recurred, and their overall survival.



‘No significant difference’

“For the entire study population with gene test scores between 11 and 25 — and especially among women aged 50 to 75 — there was no significant difference between the chemotherapy and no chemotherapy groups,” said the findings, published in the New England Journal of Medicine.

The results show that all women over 50 with a recurrence score of 0 to 25 can be spared chemotherapy and its toxic side effects.

For women under 50 with a score of 0 to 15, chemo can be skipped.

However, among younger women with scores 16 to 25, outcomes were slightly better in the chemotherapy group, so in those cases doctors may urge patients to consider a chemo regimen.

The results “should have a huge impact on doctors and patients,” Albain said.

“We are de-escalating toxic therapy.”

According to first author Joseph Sparano of Montefiore Medical Center in New York, “any woman with early-stage breast cancer 75 or younger should have the test and discuss the results” with her doctor.

Breast cancer is the leading cause of cancer death in women worldwide, causing some 1.7 million new cases annually and over half a million deaths.

The study’s primary funding came from the US National Institutes of Health (NIH).

Lung cancer

The second study tested a form of immunotherapy against chemo, in the most common lung cancer worldwide, known as non-small-cell lung cancer.

It found that Merck pharmaceutical’s drug Keytruda (pembrolizumab) — which famously helped former US president Jimmy Carter stave off advanced melanoma that had spread to his brain — helped lung cancer patients live four to eight months longer than chemo.

More than 1,200 people enrolled in the study, the largest clinical trial to date of pembrolizumab as a stand-alone therapy for lung cancer. The drug was approved in 2014 for melanoma and in 2015 for lung cancer.

“These are responses that are unlike anything we have seen in the past for non-small-cell lung cancer,” said lead author Gilberto Lopes, a medical oncologist at the University of Miami Health Center.

Still, he acknowledged that most patients with this form of advanced cancer will die within months, and “we need to do a lot more work.”

Lung cancer is the leading cause of cancer death worldwide, taking 1.7 million lives per year.

John Heymach, a professor at the University of Texas MD Anderson Cancer Center who was not involved in the Merck-funded study, described it as a “true milestone” and “a real important advance for patients.”

“We are now leaving an era where the only choice for non-small-cell lung cancer patients was to start with chemotherapy,” he told reporters at the ASCO conference.

“Now, the vast majority of patients can potentially receive benefits from immunotherapy instead,” he added.

“Immunotherapy is here to stay for the vast majority of non-small-cell lung cancer patients as a first-line treatment.” /cbb

source: technology.inquirer.net

Friday, June 17, 2016

Heat, not coffee, may cause cancer


Switch to an iced latte then.

Coffee poses no cancer risk; it’s the extreme heat of the beverage, or any other drink for that matter, that may be dangerous when drank, according to an international working group of scientists convened by the World Health Organization (WHO).

The scientists concluded that coffee should no longer be considered a carcinogen. It however found limited evidence that drinking very hot beverages could cause esophageal cancer.

“[It is suggested] that drinking very hot beverages is one probable cause of esophageal cancer, and that it is the temperature rather than the drinks that appears to be responsible,” said Christopher Wild, director of WHO’s International Agency for Research on Cancer.

Wild said the working group found no conclusive evidence of a carcinogenic effect from drinking coffee.

The WHO cited studies conducted in places like China, Iran, Turkey and South America, where coffee and tea are traditionally drank very hot.

The findings suggested that the risk of esophageal cancer increased with the temperature at which the beverage was drunk.

“Smoking and alcohol drinking are major causes of esophageal cancer, particularly in many high-income countries,” according to Wild.

High incidence

“However, the majority of esophageal cancers occur in parts of Asia, South America and East Africa, where regularly drinking very hot beverages is common and where the reasons for the high incidence of this cancer are not as well understood,” he said.

The WHO said esophageal cancer is the eighth most common cause of cancer worldwide and one of the main causes of cancer deaths, with 400,000, nearly five percent of all cancer deaths, recorded in 2012.

The WHO said the number of esophageal cancer cases that could be linked to drinking very hot beverages was not known.

source: lifestyle.inquirer.net

Friday, October 2, 2015

Link between tallness, higher cancer risk—study


PARIS, France—Being tall is linked to a higher risk of cancer, especially for women, said research Thursday drawn from physical and health data for five million people in Sweden.

For every 10 centimeters (four inches) over one meter in height, the odds of developing cancer increased by 10 percent in men and 18 percent in women, the research team reported at a medical conference in Barcelona.

A Swedish woman 1.72 m (six feet) tall, for example, was about a third more likely to contract cancer than a woman of 1.52 m.

The findings, which have not been published in a scientific journal, support similar links found in other studies between height and elevated cancer risk—but the researchers said their work was based on the largest group of men and women yet.

It was not clear if their findings would translate to people who live in different climates, with different diets and genetic backgrounds.

The findings, unveiled at a meeting of the European Society for Paediatric Endocrinology, looked at birth, health and military records of 5.5 million people born between 1938 and 1991. The tallest was 2.25 m in adulthood.

It found that for every extra 10 cm, a woman had a 20-percent higher risk of breast cancer, while there was a jump of 30 percent for every 10 cm in melanoma risk for both genders.

A United States study in 2013, done among only women, had found a 13 percent higher risk of developing certain cancers for each 10 cm of height.

The new research was met with some scepticism by outside experts who questioned the methodology, and stressed there was a much stronger cancer risk link with factors such as genetics or obesity.

Rather than tallness “causing” an elevated cancer risk, factors like growth hormones may be influencing both traits, they pointed out.

“It sounds an odd relationship at first glance, but it is actually very plausible that the risk of cancer in a person should be related to the number of cells in their body, since that determines the number of cells ‘at risk,'” Dorothy Bennett, a scientist at University of London said in comments issued by the Science Media Centre.

“A cancer arises by mutations from a single normal cell. Bigger people have more cells.”

Mel Greaves, a researcher at the Institute of Cancer Research in London, added: “Tall people shouldn’t worry that they are destined to get cancer.”

source: technology.inquirer.net

Thursday, May 14, 2015

Vitamin B3 reduces risk of skin cancer–study


MIAMI–A certain type of vitamin B3 may help reduce the risk of non-melanoma skin cancers by 23 percent, according to research released Wednesday ahead of a major US cancer conference.

Known as nicotinamide, the vitamin supplement was shown to enhance DNA repair and restore the skin’s immunity, said the findings presented in advance of the American College of Clinical Oncology Conference in Chicago later this month.


“This is the first clear evidence that we can reduce skin cancers using a simple vitamin, together with sensible sun protection,” said lead researcher Diona Damian, a professor of dermatology at the University of Sydney.

The study involved 386 patients who had been diagnosed with at least two skin cancers — such as basal cell carcinoma and squamous cell carcinoma — in the last five years.


Half were randomly assigned to take 500 milligrams twice daily of nicotinamide, while the other half took a placebo.

Researchers stressed that the study involved nicotinamide, and not nicotinic acid, another common form of vitamin B3 that has been associated with some side effects including flushing and low blood pressure.

The treatment was well-tolerated in the patients, whose ages ranged from 30 to 91 and who were considered high-risk due to their history of skin cancer.

When patients stopped taking the supplements, their risk of getting skin cancer rose again about six months later, indicating that the benefit can only be gained if the supplements are taken consistently.

“This is ready to go straight into the clinic,” said Damian.

However, she cautioned that the treatment was not tested as a remedy or prevention strategy for the general public, and that sunscreen is still necessary to protect against skin cancer.

source: technology.inquirer.net

Sunday, October 26, 2014

Jack Bruce, bassist of rock band Cream, dies aged 71


LONDON – Jack Bruce, a founding member of British psychedelic band Cream, died on Saturday aged 71 after a long battle against liver disease, his family announced.

Although an accomplished songwriter, Bruce was best known as vocalist and bass guitarist alongside Eric Clapton and drummer Ginger Baker in the 1960s supergroup.

“It is with great sadness that we, Jack’s family, announce the passing of our beloved Jack: husband, father, granddad, and all round legend,” said a family statement.

“The world of music will be a poorer place without him but he lives on in his music and forever in our hearts.”

Tony Iommi, guitarist with heavy rockers Black Sabbath called Bruce “a major influence in music and an amazing bass player and singer” while Whitesnake’s Bernie Marsden told the BBC that Bruce was “a true legend.”

“That word gets banded about sometimes but Jack Bruce was certainly in that kind of sphere,” he said.

Publicist Claire Singers confirmed that Bruce had died at his home in Suffolk, south east England, on Saturday.

Bruce was born in Lanarkshire, Scotland, on May 14, 1943 and learned to play the bass in his teens.

He left the Royal Scottish Academy of Music and Drama, where he was studying cello and musical composition, after they banned him from playing jazz.

Cream formed in 1966 and went on to sell 35 million records worldwide before splitting up two years later.

Bruce co-wrote most of the band’s biggest hits, including “Sunshine of Your Love” and “I Feel Free.”

He later worked with Frank Zappa and Lou Reed and was a member of Ringo Starr’s All-Starr Band, but suffered health problems after being diagnosed with liver cancer in 2003. He received an organ transplant in the same year.

source: entertainment.inquirer.net

Thursday, October 24, 2013

Women urged: Fight for your man’s prostate


MANILA, Philippines—Women fighting for the early detection of prostate cancer?

Since men are deemed too stubborn to have themselves checked, women have been targeted to lead the fight against the third cause of death among Filipino men.

Spearheaded by Janssen Phils. and Healthway Medical Clinics, the campaign “Fight for your Man” reaches out to women to get the men in their lives who are at least 40 years old and have a family history of prostate cancer to have themselves screened for the disease.

Sonia Roco, whose husband Sen. Raul Roco died from complications of prostate cancer on Aug. 5, 2005, said she was working on an advocacy campaign for awareness of the disease because that was what her husband had wanted to do.


“More lives could be saved by early detection if the men would cooperate. They hate going to hospitals to see a doctor,” she said.

The late senator, who was diagnosed with prostate cancer in 1996, kept his condition a secret. He went into remission following treatment.

His wife attributed the recurrence of the cancer to the stress of running for president in 1998 and 2004.

“By 2004, he was beginning to feel pain all over. He was in the mountains in Mindanao in the middle of the campaign when he said the pain was getting to be unbearable. We came back and fought till the end,” she said.

Dr. Josephine Tolentino, an oncologist who heads the prostate screening campaign, said that while prostate cancer remained the most commonly diagnosed cancer among men, poverty and poor health service delivery contributed to a low level of consciousness about it.

“So we promote awareness to get them to do a regular screening. But in our culture, men are afraid of going to doctors because they don’t want to know they are sick. So we talk to the wife, sister, daughter, granddaughter. We ask them to intervene,” Tolentino said.

Urologist Dr. Jaime Songco said the risk of developing prostate cancer increased with age.

He said the initial symptoms, which do not show up in the early stage, are a weak and reduced urine flow, urinating more often, especially at night, and difficulty passing urine.

As the prostate cancer advances, the symptoms would include lower urinary tract problems, blood in the urine and painful urination. In the advanced stage, the patient begins to feel bone pain.

“We have to create a foundation, an advocacy group to support educating the men because right now, there’s no [advocacy group among] men,” Songco said.

“So if you have men in your lives, have them screened because in the early stages it’s really curable,” he said.

The tests used to diagnose prostate cancer include urine tests, ultrasound and the prostate specific antigen (PSA) test.

source: lifestyle.inquirer.net

Tuesday, October 22, 2013

3 Ways to Make a Difference for Mesothelioma Victims


Make a Difference Day is approaching! October 26 is the day to make a difference; are you wondering how to do so?

So many individuals in the United States are affected by mesothelioma, a rare, painful, and incurable form of cancer caused by asbestos exposure. Making a difference in their lives for just one day might be the perfect answer. Here are a few ways you can reach out to those affected by mesothelioma:




Spend some time with those affected by mesothelioma. Every year, around 3,000 new mesothelioma patients are diagnosed1. It could be your mother or father, or a close friend who has been affected by the disease, or someone you do not know at all. No matter who it is, volunteering your time to comfort, converse, and live with a mesothelioma patient will surely make a difference.




Spread awareness of the disease. If you can't find the time to spend with a mesothelioma patient in person, spreading awareness of the disease is just as great of an effort. We have more than a few inspirational images and infographics that you are free to share across your social networks, as well as information on our website. There are people fighting all over the country for mesothelioma victims' rights, so it should not be hard to find news to spread.


Support the cause. Funding for mesothelioma research receives is far less than other cancers2, so any support is welcome by research centers and mesothelioma patients alike. Without proper funding, this disease remains one step further from a cure. The Mesothelioma Cancer Alliance has provided a list of charities you can donate to on their website.

source: braytonlaw.com

Monday, August 26, 2013

Is cancer caused by negative emotions?


A homeopathic doctor believes that cancer is caused by negative emotions. For instance, cancer in the left breast is born out of a loss, and femininity issues. Cancer in the right breast is spurred by conflicts with the opposite sex. Cancer in the small intestines is a result of prolonged depression. Anger, meanwhile, can result in cancer in the large intestine.

Indian-born Dr. Shaji Kudiyat maintains that the soul or life force, the mind and emotions, and bodily functions are all intimately linked. Positive and negative experiences and impressions can thus have an impact on physical functions. Feelings of anger, worry or sorrow can subsequently make the body more vulnerable.

On the other hand, when the patient awakens its spiritual identity or begins to understands itself as a life force and attunes itself to love and hope, healing can begin.

At the start of his medical practice, Kudiyat realized that cancer was being treated without understanding its root causes. “Today’s cancer treatments mainly focus on the identification and rectification of the tumor growth,” he says. “It is achieved by surgically removing the tumor or by destroying it by chemotherapy or radiation.”

He realize that the things he learned in medical school had their limitations. Science maintains that genes are responsible for life and that the body is made of material components and biochemical actions and reactions. However, they don’t have the ability to think, feel or express emotions.

Based on his researches, Kudiyat says he discovered that there is a nonmaterial element, a living energy, that actually makes the body function.

“This energy can be easily identified as the wave which the doctors and nurses monitor in all intensive care units,” he says. “My curious mind started searching for solutions by which we can overcome scientific limitations.”

‘Dynamic Science’

This led him to form what he calls “Dynamic Science,” which attempts to explain how the mind, the vital force (soul) and DNA (which decides all physical functions) are interconnected.

“It answers many questions and helps solve some difficult problems including diseases like cancer,” says Kudiyat.

“Dynamic Science can explain how our thoughts decide the genetic nature of our own DNA. So when we have positive thoughts, the vibrations can modify the DNA constructively, resulting in a curative DNA.  Similarly, negative thoughts modify the DNA, resulting in the unhealthy transformation of the DNA, producing diseases including cancer.”

Kudiyat observes that cancer patients follow a certain pattern: They held deep-seated negative emotions and hurts before they developed cancer.




“Through Dynamic Science, we identify the root cause of cancer and chronic diseases as  negative mental states other than nutritional deficiency and lack of proper rest, sleep and exercise,” says Kudiyat.

Nonsurgical alternative

He offers a nonsurgical alternative. First, he makes a holistic case study of the patient by knowing the personality. Then the patient and family attend a group counseling session. This includes probing the psychological reasons for the cancer. He  helps the patient understand what is needed to be done to eliminate the causes.

He then prescribes homeopathic medicine and encourages yoga, meditation, prayer, music therapy, laughter therapy and other techniques to let the mind be at peace.

Kudiyat shares a success story. A married lady had conflicts with her husband which remained unresolved for many years. This hardened her. She slowly developed a lump in the right breast which became malignant. After she consulted several doctors, her biopsy confirmed that she had invasive ductal carcinoma.

Although she underwent mastectomy, she also consulted Dr. Kudiyat for a lifestyle change. The patient realized that beneath the hardened heart was a wellspring of peace and happiness. She learned to forgive, let go, move on and trust again.

“That was in 1997; she’s still alive,” he says.

Dr. Shaji Kudiyat will hold a lecture on “Dynamic Science: Approach to Cancer Prevention & Treatment” on Sept. 5, from 6 to 9:30 p.m., at Santuario de San Antonio, Buffalo cor. Duke St., Greenhills. For details, call 0917-5275002.

source: lifestyle.inquirer.net








Friday, August 9, 2013

‘Five Easy Pieces’ star Karen Black dead at 74


LOS ANGELES – Karen Black, the prolific actress who appeared in more than 100 movies and was featured in such counterculture favorites as “Easy Rider,” ”Five Easy Pieces” and “Nashville,” has died.

Black’s husband, Stephen Eckelberry, said the actress died Wednesday from complications from cancer. She was 74.

Known for her full lips and thick, wavy hair that seemed to change color from film to film, Black often portrayed women who were quirky, troubled or threatened. Her breakthrough was as a prostitute who takes LSD with Dennis Hopper and Peter Fonda in 1969′s “Easy Rider,” the hippie classic that helped get her the role of Rayette Dipesto, a waitress who dates — and is mistreated by — an upper-class dropout played by Jack Nicholson in 1970′s “Five Easy Pieces.”

Cited by The New York Times as a “pathetically appealing vulgarian,” Black’s performance won her an Oscar nomination and Golden Globe Award. She would recall that playing Rayette really was acting: The well-read, cerebral Black, raised in a comfortable Chicago suburb, had little in common with her relatively simple-minded character.

“If you look through the eyes of Rayette, it looks nice, really beautiful, light, not heavy, not serious. A very affectionate woman who would look upon things with love, and longing,” Black told Venice Magazine in 2007.

“A completely uncritical person, and in that sense, a beautiful person. When (director) Bob Rafelson called me to his office to discuss the part he said, ‘Karen, I’m worried you can’t play this role because you’re too smart.’ I said ‘Bob, when you call “action,” I will stop thinking,’ because that’s how Rayette is.’”

In 1971, Black starred with Nicholson again in “Drive, He Said,” which Nicholson also directed. Over the next few years, she worked with such top actors and directors as Richard Benjamin (“Portnoy’s Complaint”), Robert Redford and Mia Farrow (“The Great Gatsby”) and Charlton Heston (“Airport 1975″). She was nominated for a Grammy Award after writing and performing songs for “Nashville,” in which she played a country singer in Robert Altman’s 1975 ensemble epic. Black also starred as a jewel thief in Alfred Hitchcock’s last movie, “Family Plot,” released in 1976.

“We used to read each other poems and limericks and tried to catch me on my vocabulary,” she later said of Hitchcock. “He once said, ‘You seem very perspicacious today, Miss Black.’ I said, ‘Oh, you mean “keenly perceptive?” ‘Yes.’ So I got him this huge, gold-embossed dictionary that said ‘Diction-Harry,’ at the end of the shoot.”

The actress would claim that her career as an A-list actress was ruined by “The Day of the Locust,” a troubled 1975 production of the Nathanael West novel that brought her a Golden Globe nomination but left Black struggling to find quality roles.

By the end of the ’70s, she was appearing in television and in low-budget productions. Black received strong reviews in 1982 as a transsexual in Altman’s “Come Back to the Five and Dime, Jimmy Dean, Jimmy Dean.” But despite working constantly over the next 30 years, she was more a cult idol than a major Hollywood star. Her credits included guest appearances on such TV series as “Law & Order” and “Party of Five” and enough horror movies, notably “Trilogy of Terror,” that a punk band named itself “The Voluptuous Horror of Karen Black.”

Black was married four times. She is survived by Eckelberry, a son and a daughter.

source: entertainment.inquirer.net

Sunday, July 14, 2013

More evidence of prostate cancer, omega-3 link


WASHINGTON—US scientists said Wednesday they have confirmed a surprising 2011 study that found a higher risk of prostate cancer among men who consume omega-3 fatty acids, raising new questions about the safety of supplements.

The research in the Journal of the National Cancer Institute reported a 71 percent higher risk for dangerous high-grade prostate cancer among men who ate fatty fish or took fish-oil supplements, which are often touted for their anti-inflammatory properties.

“We’ve shown once again that use of nutritional supplements may be harmful,” said Alan Kristal, researcher at the Fred Hutchinson Cancer Research Center and senior author of the paper.

Scientists are still puzzled as to why omega-3s appear linked to a greater risk of prostate cancer, but they said the findings suggest they are somehow involved in the formation of tumors.

The same team of researchers published similar findings in 2011, linking high blood concentrations of DHA to a more than double risk of high-grade prostate cancer, which is more likely to be fatal than other types.

A large European study also found the same omega-3 and prostate cancer link.

“The consistency of these findings suggests that these fatty acids are involved in prostate tumorigenesis and recommendations to increase long-chain omega-3 fatty acid intake, in particular through supplementation, should consider its potential risks,” the US study said.

The difference in blood concentrations of omega-3 fatty acids between the highest and lowest risk groups was about 2.5 percentage points (3.2 percent vs. 5.7 percent), or just higher than the effect of eating salmon twice a week, Kristal said.

The latest study was based on an analysis of specimens and data from a large randomized, controlled trial that tested whether selenium and vitamin E would reduce prostate cancer risk.

The trial, known as SELECT (the Selenium and Vitamin E Cancer Prevention Trial), found that vitamin E raised the prostate cancer risk and selenium showed no impact either way.

For the July 11 study in the Journal of the National Cancer Institute, researchers analyzed the data on 834 men diagnosed with prostate cancer and compared them to a random sample of 1,393 taken from the SELECT trial.

Those who had high blood concentrations of the fatty acids EPA, DPA and DHA were shown to have a 71 percent increased risk of high-grade prostate cancer.

The increased risk of low grade prostate cancer was 44 percent higher in those with elevated fatty acid levels, and the combined risk was 43 percent for all prostate cancers.

Due to the nature of the study, it was not possible to tell for certain whether the elevated blood levels were due to men taking supplements or eating fish rich in omega-3s.

However, Franklin Lowe, associate director of the department of urology at St. Luke’s-Roosevelt Hospital in New York, said the findings should remind consumers that supplements may not help, and may even do harm.

“In general, there is nothing that has been proven to actually limit the risk of prostate cancer,” said Lowe, who was not involved in the study.

“For the most part, doctors do not recommend this stuff because it is unclear what the true benefits are for most of the supplements that people take.”—Kerry Sheridan

source: lifestyle.inquirer.net

Thursday, July 11, 2013

US study raises alarm on omega-3


WASHINGTON—US scientists say they have confirmed a surprising 2011 study that found a higher risk of prostate cancer among men who consume omega-3 fatty acids, raising new questions about the safety of supplements.

The research in the Journal of the National Cancer Institute reported a 71 percent higher risk for dangerous high-grade prostate cancer among men who ate fatty fish or took fish-oil supplements, which are often touted for their anti-inflammatory properties.

“We’ve shown once again that use of nutritional supplements may be harmful,” said Alan Kristal, researcher at Fred Hutchinson Cancer Research Center and senior author of the paper.

Scientists are still puzzled as to why omega-3s appear linked to a greater risk of prostate cancer, but they said the findings suggested they were somehow involved in the formation of tumors.

The same team of researchers published similar findings in 2011, linking high blood concentrations of DHA to a more than double risk of high-grade prostate cancer, which is more likely to be fatal than other types.



Potential risks

A large European study also found the same omega-3 and prostate cancer link.

“The consistency of these findings suggests that these fatty acids are involved in prostate tumorigenesis and recommendations to increase long-chain omega-3 fatty acid intake, in particular through supplementation, should consider its potential risks,” the US study said.

The difference in blood concentrations of omega-3 fatty acids between the highest and lowest risk groups was about 2.5 percentage points (3.2 percent vs 5.7 percent), or just higher than the effect of eating salmon twice a week, Kristal said.



Controlled trial

The latest study was based on an analysis of specimens and data from a large randomized, controlled trial that tested whether selenium and vitamin E would reduce prostate cancer risk.

The trial, known as Select (the Selenium and Vitamin E Cancer Prevention Trial), found that vitamin E raised the prostate cancer risk and selenium showed no impact either way.

For the July 11 study in the Journal of the National Cancer Institute, researchers analyzed the data on 834 men diagnosed with prostate cancer and compared them to a random sample of 1,393 taken from the Select trial.

Increased risk

Those who had high blood concentrations of the fatty acids EPA, DPA and DHA were shown to have a 71 percent increased risk of high-grade prostate cancer.

The increased risk of low-grade prostate cancer was 44 percent higher in those with elevated fatty acid levels, and the combined risk was 43 percent for all prostate cancers.

Due to the nature of the study, it was not possible to tell for certain whether the elevated blood levels were due to men taking supplements or eating fish rich in omega-3s.

Benefits unclear

However, Franklin Lowe, associate director of the department of urology at St. Luke’s-Roosevelt Hospital in New York, said the findings should remind consumers that supplements may not help, and may even do harm.

“In general, there is nothing that has been proven to actually limit the risk of prostate cancer,” said Lowe, who was not involved in the study.

“For the most part, doctors do not recommend this stuff because it is unclear what the true benefits are for most of the supplements that people take.”

source: business.inquirer.net

Tuesday, March 26, 2013

The Henderson cancer doctor who earned more than Steve Wynn and Sheldon Adelson

Dr. Rajesh C. Shrotriya earned $25 million last year — millions more than Gary Loveman, Steve Wynn and Sheldon Adelson.

Shrotriya was the highest paid executive in the Las Vegas Valley in 2012. He earned $25.2 million in compensation, including salary, bonus, stock awards, options and benefits, according to filings with the Securities and Exchange Commission.

He made his money working at a company most locals have never heard of: Spectrum Pharmaceuticals, a Henderson drug company.

But with competition from abroad and a bevy of lawsuits launched this month, Shrotriya stands to earn far less this year.

Spectrum’s global corporate headquarters is an office building on South Eastern Avenue. The company also has a research and development facility in Irvine, Calif., and international offices in Sherbrooke, Quebec, and Mumbai, India.

The small biotechnology company acquires, develops and commercializes late-stage clinical and commercial drugs, mostly those that fight cancer.

Shrotriya, 67, whom colleagues call “Dr. Raj,” lives by the Microsoft mantra of not fearing failure, but failing quickly if you do.

Shrotriya spent 18 years at Bristol-Myers Squibb Company. He became president of Spectrum in 2000 and CEO in 2002. He spearheaded major changes in the company’s business strategy and coordinated a structural reorganization.

A 2007 profile in the Orange County Register credited him with saving Spectrum because he worked without pay while the company struggled financially.

A clinical trial had shown one of Spectrum's drugs to be ineffective, and stock plummeted from $3.64 a share to 10 cents a share. Shrotriya’s ascension was announced around the same time. He was named CEO on a Friday. By Monday, he had laid off all but 10 of the company’s 70 employees, according to the Register.

Soon after, the company landed new financing and Shrotriya once again began receiving a paycheck. Since then, he developed partnerships with drug manufacturing companies and grew Spectrum into a company that was labeled one of the “Best Companies to Work For” in Southern California.

Shrotriya is said to be quick to jettison drugs that don’t show promise, as he is with employees who flounder. He describes all Spectrum workers as "the CEOs of their own area" with the right and responsibility to do what's needed to excel, according to the Register.

On a wall in the Spectrum office hangs 52 framed photographs of employees who have signed pledges to pursue the company’s mission.

“Once a week, I look at those 52 faces,” Shrotriya told the Register. “Maybe 43 are working on all eight cylinders. Nine aren’t — three of them probably will be fired, three we can work on and three are getting there.”

A local oncologist who is working on a clinical trial with Spectrum said Southern Nevada is fortunate to have the company in its backyard, considering the state’s bid to diversify.

Dr. Matthew Schwartz, a radiation oncologist at the Comprehensive Cancer Centers of Nevada, said his clinic is one of 11 around the country working with Spectrum on a trial for Zevalin, an injected drug that binds itself to cancer cells and delivers radiation directly to the site.

Zevalin is one of three mainstay drugs on Spectrum’s product list. The company markets two other oncology drugs, Folotyn and Fusilev.

Dr. Nicholas Vogelzang, an expert in prostate, kidney, bladder and testicular cancers at the Comprehensive Cancer Centers, said it doesn’t matter that Spectrum has a small roster, if at least one of them turns into a “one-shot miracle.”

Lately, Spectrum has been in the news for the wrong reasons.

On March 12, the company projected a weak first quarter because sales of its best-selling product, the colon cancer drug Fusilev, are dropping. Spectrum anticipates a 33 percent decline in sales of Fusilev this year compared to last year.

The Food and Drug Administration approved a version of the drug manufactured by a rival pharmaceuticals company, and a Hungarian version was approved for import.

Spectrum should still be profitable. Total revenue for the company is expected to come in at between $160 million and $180 million for 2013, thanks to the successes of Zevalin and the lymphoma drug Folotyn. But analysts had expected profits of more than $290 million.

Following the announcement, shares of Spectrum stock fell almost 40 percent, to their lowest price in more than a year.

At least 10 law firms nationwide also announced plans for class-action lawsuits against the company. The cases will be heard in U.S. District Court in Nevada.

The firms are seeking investors who bought Spectrum stock between Aug. 8 and March 12.

Spectrum officials did not return numerous calls from VEGAS INC.

source: vegasinc.com

Monday, January 14, 2013

Doc Neeson vows to beat cancer


Angels frontman Doc Neeson has told bandmates he will among the 20 per cent of patients who beat a form of aggressive brain tumour which resulted in him being hospitalised and all tour dates being cancelled.


Neeson, who turned 66 on January 4, was admitted to hospital shortly before Christmas complaining of pins and needles. He was immediately placed on a programme of chemotherapy and radiotherapy.

His plight has ended plans for him to front a second version of the iconic Australian pub-rock band, which would tour in competition with a line-up fronted by former Screaming Jets singer David Gleeson.

Drummer Buzz Bidstrup told News Limited of the diagnosis: ”On a scale of one to four it’s a four. But he’s incredibly stoic and accepting; he’s in great spirits.

”Doc’s looking at it as he’s one of the 20 per cent that can make it, which is the only attitude you can have.”

Neeson was in February to tour with a version of The Angels, best known for songs such as Am I Ever Gonna See Your Face Again, Marseilles and Face The Day, which includes former members who had never all played together before.

That tour has now been cancelled while the version including Rick and John Brewster will press on with their own plans in February. Bidstrup said he hoped Neeson’s illness would end the feuding.

John Brewster told AAP:  ”All we can hope is Doc makes a complete recovery and nothing else matters.
Together we’ve done some incredibly hard yards and we formed a very long-term association. Whether we’ve seen things the same ways or not in the last few years is completely irrelevant to what’s going on right now.”

Bassist Chris Bailey, who is in Brewster’s Angels, has recently battled jaw cancer. Neeson has been in constant pain since a 1999 car accident.

Bidstrup told The Australian: “It’s very intense treatment but once he’s done the first lot of chemo he’ll know how he’s travelling and then he’s got another long road after that. But there is a period of time in between and if he’s feeling good and wants to play then we’ll be there with him.”

– Steve Mascord

source: classicrockmagazine.com

Saturday, December 8, 2012

Hawkwind’s Huw Lloyd Langton dies


Hawkwind have announced that former member Huw Lloyd Langton has died after a cancer battle. He was 61.

The guitarist joined the band in 1970, appearing on their self-titled first album. He returned for a second stint in 1979 and remained for nine years, ultimately appearing on ten of their records.

He’d been a member of Widowmaker and played as part of Leo Sayer’s band. He’d continued working with Dave Brock – the pair recently performed a charity concert for the Devon Air Ambulance Trust. He also made regular guest appearances with Hawkwind, or performed support slots.

He fronted his own band, the Lloyd Langton Group, which released nine albums. He also played session guitar for the Meads of Asphodel.

The band say in a statement: “Our great friend and fellow musician Huw Lloyd Langton has sadly lost his long battle with cancer. He passed away peacefully last night (Thursday) at home, with his wife Marion by his side.

“Huw had been bravely fighting cancer for a couple of years, but was determined not to let the battle affect his day to day life. He continued to play his guitar, laugh, joke and share the great love he had in his heart, with all who knew him.

“As he wished, he was at home when the time came.

“Huw was one of the great guitarists with an individual style and character. He is gone but never forgotten by any of us. He will live on in our music and in our hearts.

“A book of condolence has been opened.”

source: classicrockmagazine.com

Monday, November 5, 2012

Dio fans force action over ignored cancer


Ronnie James Dio fans have helped bring attention to the ignored form of cancer that killed the iconic singer.

Cash raised by the Stand Up And Shout Cancer Fund was instrumental in forcing the US government into action over gastric cancer, says widow Wendy Dio – and the resulting research could benefit hundreds of thousands of people.

The charity was launched soon after the singer’s death in 2010. Since then, Dio fans have contributed $600,000.

Wendy tells Blairing Out: “We gave the hospital Ronnie was at $117,000 and they put it to gastric cancers. Before that there were no government funds for gastric cancer research.


“With our seed money they were able to go to the government and say, ‘We’ve got funding for this.’ The government gave them a grant of $11 million. That was amazing.”

Wendy says she cried when she heard Dio’s bandmate Tony Iommi had also been diagnosed with cancer. She says: “We didn’t talk about it – he lives in England, I live here. But I sent him lots of encouragement, letters and things.”

Meanwhile, Sharon Osbourne has revealed she underwent a double mastectomy after her own cancer scare.

She’d fought colon cancer several years ago, and recently discovered she was carrying a gene which increased her chances of contracting the disease in her breasts. She made the decision to have them removed.

The wife and manager of Black Sabbath singer Ozzy tells Hello: “As soon as I found out I had the gene I thought, ‘The odds are not in my favour.’

“I’ve had cancer before and I didn’t want to live under that cloud. I decided to just take everything off. For me it was a no-brainer. I don’t even think of my breasts in a nostalgic way – I just wanted to be able to live my life without that fear all the time.”

source: classicrockmagazine.com